Efficacy of Circulating Tumor Cell Count–Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer-Reference-Cited by-同舟云学术

Efficacy of Circulating Tumor Cell Count–Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer

Published:2021-01-01 Issue:1 Volume:7 Page:34
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Bidard François-Clément¹²,Jacot William³,Kiavue Nicolas¹,Dureau Sylvain⁴,Kadi Amir⁴,Brain Etienne¹,Bachelot Thomas⁵,Bourgeois Hugues⁶,Gonçalves Anthony⁷,Ladoire Sylvain⁸,Naman Hervé⁹,Dalenc Florence¹⁰,Gligorov Joseph¹¹,Espié Marc¹²,Emile George¹³,Ferrero Jean-Marc¹⁴,Loirat Delphine¹⁵,Frank Sophie¹⁵,Cabel Luc¹,Diéras Véronique¹⁶¹⁷,Cayrefourcq Laure¹⁸,Simondi Cécile¹⁹,Berger Frédérique⁴,Alix-Panabières Catherine¹⁸,Pierga Jean-Yves¹⁵

Affiliation:

1. Department of Medical Oncology, Institut Curie, UVSQ and Paris-Saclay University, Saint-Cloud, France

2. INSERM Center of Clinical Investigations in Biotherapies of Cancer (CIC-BT) 1428, Paris, France

3. Department of Medical Oncology, Institut du Cancer de Montpellier (ICM), Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Montpellier University, Montpellier, France

4. Biometry Unit, Institut Curie, PSL Research University, Paris, France

5. Department of Medical Oncology, Centre Léon Bérard, Lyon, France

6. Department of Medical Oncology, Victor Hugo Clinic, Le Mans, France

7. Department of Medical Oncology, Institut Paoli-Calmettes, CRCM, Aix-Marseille University, Marseille, France

8. Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France

9. Department of Medical Oncology, Centre Azuréen de Cancérologie, Mougins, France

10. Department of Medical Oncology, Institut Claudius Regaud, Toulouse, France

11. Department of Medical Oncology, Hôpital Tenon, Sorbonne Université, Paris, France

12. Department of Medical Oncology, Hôpital Saint-Louis, Paris, France

13. Department of Medical Oncology, Centre François Baclesse, Caen, France

14. Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France

15. Department of Medical Oncology, Institut Curie, Université de Paris, Paris, France

16. Formerly with Department of Medical Oncology, Institut Curie, Paris, France

17. Now with Department of Medical Oncology, Centre Eugène Marquis, Rennes, France

18. Laboratory of Rare Human Circulating Cells, University Medical Center of Montpellier, EA 2415, Montpellier University, Montpellier, France

19. Clinical Research Department, Institut Curie, PSL Research University, Paris, France

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2772793/jamaoncology_bidard_2020_oi_200082_1609897937.04468.pdf

Reference25 articles.

1. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort.;Gobbini;Eur J Cancer,2018

2. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.;Hammond;J Clin Oncol,2010

3. Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights.;Ng;J Natl Cancer Inst,2015

4. Tamoxifen in the treatment of breast cancer.;Osborne;N Engl J Med,1998

5. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer.;Wilcken;Cochrane Database Syst Rev,2003

Cited by 110 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the impact of circulating tumor cells: Two decades of discovery and clinical advancements in solid tumors;Critical Reviews in Oncology/Hematology;2024-11

2. An electrochemical biosensor based on mild reduction-activated CRISPR/Cas12a system for sensitive detection of circulating tumor cells;Biosensors and Bioelectronics;2024-10

3. Circulating tumor cells: from new biological insights to clinical practice;Signal Transduction and Targeted Therapy;2024-09-02

4. Liquid biopsy: paving a new avenue for cancer research;Cell Adhesion & Migration;2024-09

5. Development and Validation of a Multi-marker Liquid Bead Array Assay for the simultaneous detection of PIK3CA and ESR1 hotspot mutations in single circulating tumor cells (CTCs);Heliyon;2024-09